| | | | • July 27, 2010 | SurModics and EGEN Announce Collaboration with Potential for Long-term Delivery of siRNA | | • Aug 7, 2009 | EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development | | • June 4, 2009 | EGen Corporation Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer | | • Sep 16, 2008 | Expression Genetics' Senior Vice President/CSO, Khursheed Anwer, Ph.D., Interviewed by Pharmatelevision at Bio 2008 (no longer available) | | • Sep 5, 2008 | Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover | | • Aug 4, 2008 | Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing | | • Oct 30, 2007 | Expression Genetics, Inc. Receives SIBR Grant from National Cancer Institute for Development of EGEN-001 for Treatment of Brain Cancer | | • July 20, 2007 | Expression Genetics, Inc. Announces Further Clinical Advancement of its Gene-Based IL-12 Therapy Co-administered with Standard Chemotherapy for Treatment of Ovarian Cancer | | • May 2, 2007 | Expression Genetics, Inc. Receives Orphan Drug Grant from FDA for Clinical Development of EGEN-001 for Treatment of Ovarian Cancer | | • April 16, 2007 | | | • February, 2007 | Expression Genetics, Inc. Announces planned move to Hudson Alpha Institute of Biotechnology in the second half of 2007. | | | | | | | • April 28, 2006 | Expression Genetics, Inc. Announces EGEN-001 Cancer Therapeutic Has Been Included in the Top 100 Great Investigational Drug List | | • October 17, 2005 | | | • June, 2005 | IND approval for ovarian cancer trial | | • June, 2005 | EGEN scientists present two key papers at American Society of Gene Therapy (ASGT) meeting in St. Louis | | • May, 2005 | Investigational New Drug (IND) application filed with U.S. Food and Drug Administration (FDA) for EGEN-001 treatment of ovarian cancer | | • April, 2005 | Orphan Drug status granted on EGEN-001 for ovarian cancer | | • February, 2005 | Recombinant Advisory Committee (RAC) approval of protocol for human testing of EGEN-001 | | • January, 2005 | Series A financing round completed |
|
